Predictors of Long-Acting Injectable Antipsychotic Medication Use in Patients with Schizophrenia Spectrum, Bipolar, and Other Psychotic Disorders in a US Community-based, Integrated Health System

被引：1
作者：
Alavi, Mubarika [1 ]
Ridout, Samuel J. [2 ]
Lee, Catherine [1 ]
Harris, Brooke [3 ]
Ridout, Kathryn K. [1 ,2 ]
机构：
[1] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[2] Kaiser Permanente Northern Calif, Permanente Med Grp, Oakland, CA USA
[3] Kaiser Permanente Northern Calif, Kaiser Fdn Hosp, Oakland, CA USA
来源：
SCHIZOPHRENIA BULLETIN OPEN | 2024年 / 5卷 / 01期
关键词：
schizophrenia; bipolar disorder; psychotic disorders; treatment adherence; health inequities; ORAL ANTIPSYCHOTICS; FOLLOW-UP; ADHERENCE; MORTALITY; COHORT; NONADHERENCE; METAANALYSIS;
D O I：
10.1093/schizbullopen/sgae011
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Background and Hypothesis Long-acting injectable (LAI) antipsychotics improve patient outcomes and are recommended by treatment guidelines for patients with limited medication adherence in schizophrenia spectrum, bipolar, and other psychotic disorders. Reports of LAI antipsychotic use in these disorders and if use aligns with treatment guidelines are lacking. This study aimed to report patient characteristics associated with LAI antipsychotic use in these disorders. Study Design Retrospective observational study of patients >= 18-years-old with bipolar or psychotic disorders at a large, integrated, community-based health system. Patient demographic and clinical characteristics served as exposures for the main outcome of adjusted odds ratio (aOR) for LAI versus oral antipsychotic medication use from January 1, 2017 to December 31, 2023. Study Results There were N = 2685 LAI and N = 31 531 oral antipsychotic users. Being non-white (aOR = 1.3-2.0; P < .0001), non-female (aOR = 1.5; P < .0001), from a high deprivation neighborhood (NDI, aOR = 1.3; P < .0007), having a higher body mass index (BMI, aOR = 1.3-1.7; P < .0009), having a schizophrenia/schizoaffective (aOR = 5.8-6.8; P < .0001), psychotic (aOR = 1.6, P < .0001), or substance use disorder (aOR = 1.4; P < .0001), and outpatient psychiatry (aOR = 2.3-7.5; P < .0001) or inpatient hospitalization (aOR = 2.4; P < .0001) utilization in the prior year with higher odds and age >= 40 (aOR = 0.4-0.7; P < .0001) or bipolar disorder (aOR = 0.9; P < .05) were associated with lower odds of LAI use. Non-white, non-female, age 18-39, and high NDI patients had higher LAI use regardless of treatment adherence markers. Smoking and cardiometabolic markers were also associated with LAI use. Conclusions Demographic and clinical factors are associated with increased LAI use irrespective of treatment adherence. Research on utilization variation informing equitable formulation use aligned with treatment guideline recommendations is warranted.
引用
收藏
页数：11
相关论文
共 44 条
  • [1] Schizophrenia, (2023)
  • [2] Bipolar Disorder, (2023)
  • [3] Tsai J, Rosenheck RA., Psychiatric comorbidity among adults with schizophrenia: a latent class analysis, Psychiatry Res, 210, 1, pp. 16-20, (2013)
  • [4] Crump C, Sundquist K, Winkleby MA, Sundquist J., Comorbidities and mortality in bipolar disorder: a Swedish national cohort study, JAMA Psychiatry, 70, 9, pp. 931-939, (2013)
  • [5] Correll CU, Solmi M, Croatto G, Et al., Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors, World Psychiatry, 21, 2, pp. 248-271, (2022)
  • [6] Swartz MS, Perkins DO, Stroup TS, Et al., Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study, Am J Psychiatry, 164, 3, pp. 428-436, (2007)
  • [7] Taipale H, Tanskanen A, Mehtala J, Vattulainen P, Correll CU, Tiihonen J., 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20), World Psychiatry, 19, 1, pp. 61-68, (2020)
  • [8] Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Et al., Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review, J Clin Psychopharmacol, 36, 4, pp. 355-371, (2016)
  • [9] El Abdellati K, De Picker L, Morrens M., Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis, Front Neurosci, 14, (2020)
  • [10] Geretsegger C, Pichler EM, Gimpl K, Et al., Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: prevalence before acute admission, Psychiatry Clin Neurosci, 73, 4, pp. 175-178, (2019)
12345